Antibiotics for treatment of Clostridium difficile infection in hospitalized patients with inflammatory bowel disease

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5054-5059

  Horton, Henry A ^a   Dezfoli, Seper ^a   Berel, Dror ^a   Hirsch, Julianna ^a   Ippoliti, Andrew ^a   McGovern, Dermot ^a   Kaur, Manreet ^a   Shih, David ^a   Dubinsky, Marla ^a   Targan, Stephan R ^a   Fleshner, Phillip ^a   Vasiliauskas, Eric A ^a   Grein, Jonathan ^a   Murthy, Rekha ^a   Melmed, Gil Y ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; COMPARATIVE STUDY; CROHN DISEASE; DEATH; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HEALTH CARE QUALITY; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; ULCERATIVE COLITIS; CLOSTRIDIUM INFECTIONS; DRUG EFFECTS; INFLAMMATORY BOWEL DISEASE; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; HOSPITALIZATION; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; METRONIDAZOLE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84906092884     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02606-13     Document Type: Article

References (24)

1. Leffler DA, Lamont JT. 2009. Treatment of Clostridium difficile-associated disease. Gastroenterology 136:1899-1912. http://dx.doi.org/10.1053/j.gastro.2008.12.070.
2. Das R, Feuerstadt P, Brandt LJ. 2010. Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with Clostridium difficile-associated disease. Am. J. Gastroenterol. 105:2040-2049. http://dx.doi.org/10.1038/ajg.2010.142.
3. Leung S, Metzger BS, Currie BP. 2010. Incidence of Clostridium difficile infection in patients with acute leukemia and lymphoma after allogeneic hematopoietic stem cell transplantation. Infect. Control Hosp. Epidemiol. 31:313-315. http://dx.doi.org/10.1086/651066.
4. Rodemann JF, Dubberke ER, Reske KA, Seo DH, Stone CD. 2007. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 5:339-344. http://dx.doi.org/10.1016/j.cgh.2006.12.027. (Pubitemid 46401530)
5. Issa M, Vijayapal A, Graham MB, Beaulieu DB, Otterson MF, Lundeen S, Skaros S, Weber LR, Komorowski RA, Knox JF, Emmons J, Bajaj JS, Binion DG. 2007. Impact of Clostridium difficile on inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 5:345-351. http://dx.doi.org/10.1016/j.cgh.2006.12.028. (Pubitemid 46401531)
6. Musa S, Thomson S, Cowan M, Rahman T. 2010. Clostridium difficile infection and inflammatory bowel disease. Scand. J. Gastroenterol. 45: 261-272. http://dx.doi.org/10.3109/00365520903497098.
7. Nguyen GC, Kaplan GG, Harris ML, Brant SR. 2008. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am. J. Gastroenterol. 103: 1443-1450. http://dx.doi.org/10.1111/j.1572-0241.2007.01780.x. (Pubitemid 351813903)
8. Ananthakrishnan AN, McGinley EL, Binion DG. 2008. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 57:205-210. http://dx.doi.org/10.1136/gut.2007.128231. (Pubitemid 351158048)
9. Jen MH, Saxena S, Bottle A, Aylin P, Pollok RC. 2011. Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 33:1322-1331. http://dx.doi.org/10.1111/j.1365-2036.2011.04661.x.
10. Kyne L, Hamel MB, Polavaram R, Kelly CP. 2002. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin. Infect. Dis. 34:346-353. http://dx.doi.org/10.1086/338260. (Pubitemid 34062235)
11. Nelson RL, Kelsey P, Leeman H, Meardon N, Patel H, Paul K, Rees R, Taylor B, Wood E, Malakun R. 2011. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst. Rev. 2011:CD004610. http://dx.doi.org/10.1002/14651858.CD004610.pub3.
12. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45: 302-307. http://dx.doi.org/10.1086/519265. (Pubitemid 47101025)
13. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect. Control Hosp. Epidemiol. 31:431-455. http://dx.doi.org/10.1086/651706.
14. Fujitani S, George WL, Murthy AR. 2011. Comparison of clinical severity score indices for Clostridium difficile infection. Infect. Control Hosp. Epidemiol. 32:220-228. http://dx.doi.org/10.1086/658336.
15. Ananthakrishnan AN, Oxford EC, Nguyen DD, Sauk J, Yajnik V, Xavier RJ. 2013. Genetic risk factors for Clostridium difficile infection in ulcerative colitis. Aliment. Pharmacol. Ther. 38:522-530. http://dx.doi.org/10.1111/apt. 12425.
16. Goodhand JR, Alazawi W, Rampton DS. 2011. Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment. Pharmacol. Ther. 33:428-441. http://dx.doi.org/10.1111/j.1365-2036.2010.04548.x.
17. Ananthakrishnan AN, Binion DG. 2010. Impact of Clostridium difficile on inflammatory bowel disease. Expert Rev. Gastroenterol. Hepatol. 4:589-600. http://dx.doi.org/10.1586/egh.10.55.
18. Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, Bossa F, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, Miera IS, Chowers Y, Moran GW. 2009. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection. Clin. Gastroenterol. Hepatol. 7:981-987. http://dx.doi.org/10.1016/j.cgh.2009.05.031.
19. Murthy SK, Steinhart AH, Tinmouth J, Austin PC, Daneman N, Nguyen GC. 2012. Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis. Aliment. Pharmacol. Ther. 36:1032-1039. http://dx.doi.org/10.1111/apt.12073.
20. Navaneethan U, Mukewar S, Venkatesh PG, Lopez R, Shen B. 2012. Clostridium difficile infection is associated with worse long term outcome in patients with ulcerative colitis. J. Crohns Colitis 6:330-336. http://dx.doi.org/10.1016/j.crohns.2011.09.005.
21. Jodorkovsky D, Young Y, Abreu MT. 2010. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig. Dis. Sci. 55:415-420. http://dx.doi.org/10.1007/s10620-009-0749-9.
22. Issa M, Weber LR, Skaros S, Borromeo Beaulieu DM, Emmons J, Knox JF, Lundeen S, Otterson MF, Binion DG. 2007. Decreasing rates of colectomy despite high rates of hospitalization in C. difficile infected IBD patients: a tertiary referral center experience. Gastroenterology 132:A663.
23. Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ. 2013. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment. Pharmacol. Ther. 37:122-128. http://dx.doi.org/10.1111/apt.12111.
24. Guo B, Harstall C, Louie T, Veldhuyzen van Zanten S, Dieleman LA. 2012. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment. Pharmacol. Ther. 35:865-875. http://dx.doi.org/10.1111/j.1365-2036.2012.05033.x.